ADRB3 and obesity due to melanocortin 4 receptor deficiency: Following the lead of Beecham Pharmaceuticals (now a part of GSK) and its original drug discovery programs of β3-AR agonists as potential treatments of obesity [54], numerous pharmaceutical companies have filed patents seeking exclusivity for their β3-AR agonists as potential treatment of obesity and/or diabetes as reviewed elsewhere [201].